Avadel Pharmaceuticals plc (NASDAQ:AVDL) to Post FY2022 Earnings of ($1.60) Per Share, SVB Leerink Forecasts

Avadel Pharmaceuticals plc (NASDAQ:AVDLGet Rating) – Equities researchers at SVB Leerink lifted their FY2022 earnings per share estimates for shares of Avadel Pharmaceuticals in a research report issued on Monday, May 9th. SVB Leerink analyst M. Goodman now expects that the company will post earnings per share of ($1.60) for the year, up from their previous estimate of ($1.65). SVB Leerink also issued estimates for Avadel Pharmaceuticals’ Q4 2022 earnings at ($0.24) EPS and FY2026 earnings at $3.55 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDLGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02).

AVDL has been the subject of several other reports. Zacks Investment Research raised shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 21st. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Avadel Pharmaceuticals in a report on Friday, March 18th. Finally, Craig Hallum cut their price target on shares of Avadel Pharmaceuticals from $22.50 to $20.00 in a report on Thursday, March 17th.

Shares of NASDAQ:AVDL opened at $3.68 on Thursday. The firm has a fifty day moving average price of $6.35 and a two-hundred day moving average price of $7.40. The company has a debt-to-equity ratio of 1.82, a current ratio of 9.17 and a quick ratio of 9.17. Avadel Pharmaceuticals has a one year low of $3.64 and a one year high of $11.59. The company has a market cap of $217.24 million, a price-to-earnings ratio of -2.79 and a beta of 1.13.

Institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC raised its position in shares of Avadel Pharmaceuticals by 236.5% during the 4th quarter. Kestra Advisory Services LLC now owns 33,650 shares of the company’s stock valued at $272,000 after buying an additional 23,650 shares in the last quarter. BioImpact Capital LLC purchased a new stake in shares of Avadel Pharmaceuticals during the 3rd quarter valued at $3,920,000. GSA Capital Partners LLP raised its position in Avadel Pharmaceuticals by 8.0% in the 3rd quarter. GSA Capital Partners LLP now owns 57,148 shares of the company’s stock worth $560,000 after purchasing an additional 4,215 shares during the period. Cowen AND Company LLC raised its position in Avadel Pharmaceuticals by 1.2% in the 3rd quarter. Cowen AND Company LLC now owns 2,525,452 shares of the company’s stock worth $24,749,000 after purchasing an additional 29,879 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in Avadel Pharmaceuticals in the 4th quarter worth $1,294,000. Hedge funds and other institutional investors own 59.18% of the company’s stock.

Avadel Pharmaceuticals Company Profile (Get Rating)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Read More

Earnings History and Estimates for Avadel Pharmaceuticals (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.